De Novo Pharmaceuticals is an emerging computational drug design company.
De Novo Pharmaceuticals is an emerging computational drug design company. De Novo Pharmaceuticals uses its proprietary computational software for drug design to create novel, patentable lead molecules as candidates for drug development. De Novo's proprietary algorithms can convert information from structural genomics and medicinal chemistry rapidly into new chemical designs, maximising value within a pharmaceutical partner's research portfolio. De Novo's drug discovery partners include British Biotechnology, Aventis Pharmaceuticals and NV Organon.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 26, 2001 | Series B | £16.75M | 3 | — | — | Detail |
Apr 18, 2000 | Series A | £2M | 1 | Prelude Trust | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Prelude Trust | — | Series B |
FNI Venture Capital | — | Series B |
The Cambridge Gateway Fund | — | Series B |